Charles River Laboratories International, Inc. (CRL): Operating Cash Flow
$737.65M
Year ended 2025-12-27
$582.15M
Trailing 12 months to 2026-06-27
+6.0%
3-year compound annual growth
+6.2%
5-year compound annual growth
+9.2%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-27 | $737.65M | +0.4% | 2026-02-18, From 2024-12-29 |
| 2024-12-28 | $734.58M | +7.4% | 2026-02-18, From 2023-12-31 |
| 2023-12-30 | $683.90M | +10.4% | 2026-02-18, From 2023-01-01 |
| 2022-12-31 | $619.64M | -18.6% | 2025-02-19, From 2021-12-26 |
| 2021-12-25 | $760.80M | +39.2% | 2024-02-14, From 2020-12-27 |
| 2020-12-26 | $546.58M | +13.6% | 2023-02-22, From 2019-12-29 |
| 2019-12-28 | $480.94M | +9.0% | 2022-02-16, From 2018-12-30 |
| 2018-12-29 | $441.14M | +38.7% | 2019-02-13, From 2017-12-31 |
| 2017-12-30 | $318.07M | +0.4% | 2019-02-13, From 2017-01-01 |
| 2016-12-31 | $316.90M | +3.3% | 2019-02-13, From 2015-12-27 |
| 2015-12-26 | $306.83M | n/c | 2018-02-13, From 2014-12-28 |
| 2014-12-27 | $252.13M | +20.6% | 2017-02-14, From 2013-12-29 |
| 2013-12-28 | $209.04M | +0.5% | 2016-02-12, From 2012-12-30 |
| 2012-12-29 | $208.01M | +0.6% | 2015-02-17, From 2012-01-01 |
| 2011-12-31 | $206.84M | +22.9% | 2014-02-25, From 2010-12-26 |
| 2010-12-25 | $168.24M | -22.0% | 2013-02-27, From 2009-12-27 |
| 2009-12-26 | $215.58M | -21.8% | 2012-02-27, From 2008-12-28 |
| 2008-12-27 | $275.57M | n/a | 2011-02-23, From 2007-12-30 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $737.65M | +0.4% |
| Incyte Corp (INCY) | 2025-12-31 | $1.41B | +321.5% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $713.22M | +17.1% |
| Icon PLC (ICLR) | 2025-12-31 | $1.04B | -19.5% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $2.65B | -2.3% |
| NRC Health (NRC) | 2025-12-31 | $26.45M | -23.6% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | -$34.41M | n/m |
| OmniAb, Inc. (OABI) | 2025-12-31 | -$36.45M | n/m |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | -$3.87M | n/m |
Compare CRL, INCY, MEDP, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗